ccr5 receptor การใช้

• Their patent covers a gene known as the CCR5 receptor gene.
• The virus initially infects CD4 cells via the CD4 protein and the CCR5 receptor.
• It turned out that the gene for the patients'CCR5 receptor was defective.
• The discovery of the CCR5 receptor galvanized him.
• The deletion of 32 base pairs in this gene results in nonfunctional CCR5 receptors.
• A HIV X4, which does not use the CCR5 receptor, were also detected.
• HIV that use only the CCR5 receptor are termed X4, and those that use both, X4R5.
• He also expressed frustration that activist groups have prevented newer CCR5 receptor antagonists from being tested in Europe.
• Vicriviroc binds to a small hydrophobic pocket between the transmembrane helices near the extracellular surface of the CCR5 receptor.
• Small molecule antagonists of CCR5 bind to a hydrophobic pocket formed by the transmembrane helices of the CCR5 receptor.
• "' CCR5 receptor antagonists "'are a class of small molecules that antagonize the CCR5 receptor.
• "' CCR5 receptor antagonists "'are a class of small molecules that antagonize the CCR5 receptor.
• The idea is that you end up with lots of CCR5 receptors, so the virus has more gateways into the cell,
• CCL4, also known as Macrophage inflammatory protein-1? ( MIP-1? ) is a CC chemokine with specificity for CCR5 receptors.
• Because " most of HIV strains " use the CCR5 receptor to enter a host cell, the mutation confers resistance to HIV infection.
• CCR5 ?32 is a 32-base-pair deletion that introduces a premature stop codon into the CCR5 receptor locus, resulting in a nonfunctional receptor.
• Viruses that use only the CCR5 receptor are termed R5, those that only use CXCR4 are termed X4, and those that use both, X4R5.
• Cenicriviroc is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell.
• Individuals homozygous for CCR5 ?32 do not express functional CCR5 receptors on their cell surfaces and are resistant to HIV-1 infection, despite multiple high-risk exposures.
• The location of CCR5 receptors at the cell surface, both large and small molecules have the potential to interfere with the CCR5-viral interaction and inhibit viral entry into human cells.